Former President Joe Biden was diagnosed with an "aggressive" form of prostate cancer after leaving the White House last ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

Genitourinary adverse events seen in both groups; similarly, very low rates of gastrointestinal adverse events seen with 2F SBRT, 5F SBRT.